drugset / Trial / NCT01752205
Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma
Phase 3
Unknown
120 enrolled
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and effectiveness of erlotinib and chemoradiotherapy in patients with unresectable esophageal or gastro-esophageal squamous cancer .
Timeline
- Start
- 2012-11
- Primary completion
- 2014-05
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Background | Paclitaxel | Small molecule | 45 mg/m2 | Intravenous |